PDCD1 and neoplasm: Concurrent ICB therapy with the low dose of 177Lu RIT delayed exponential tumor growth until day 30, whereas exponential growth was observed in the cold h8C3 mAb group and in the anti-PD-1 group by day 10 (Figure 2 and Figure 5e).